Invention Grant
- Patent Title: T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex
-
Application No.: US16065047Application Date: 2016-12-22
-
Publication No.: US11639374B2Publication Date: 2023-05-02
- Inventor: Fiona Chester , Andrew Alexander Knox , Jonathan Patrick Lowther , Viren Vinubhai Patel , Emma Elizabeth Baston , Ruth Martinez Hague
- Applicant: IMMUNOCORE LIMITED
- Applicant Address: GB Abingdon
- Assignee: IMMUNOCORE LIMITED
- Current Assignee: IMMUNOCORE LIMITED
- Current Assignee Address: GB Abingdon
- Agency: Fenwick & West LLP
- Priority: GB1522592 20151222
- International Application: PCT/GB2016/054032 WO 20161222
- International Announcement: WO2017/109496 WO 20170629
- Main IPC: C07K14/725
- IPC: C07K14/725 ; C07K14/47 ; A61K9/00 ; A61K35/17 ; A61K38/17 ; A61K39/395 ; A61K45/06 ; C07K16/28 ; C12N5/0783 ; A61K39/00 ; A61P35/00
Abstract:
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. Said TCRs may comprise mutations within the alpha and/or beta variable domains relative to a native NY-ESO-1 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
Public/Granted literature
- US20190002523A1 T CELL RECEPTORS SPECIFIC FOR THE NY-ESO-1 TUMOR ANTIGEN-HLA-A*02 COMPLEX Public/Granted day:2019-01-03
Information query
